Drug Combination Details
| General Information of the Combination (ID: C12590) | |||||
|---|---|---|---|---|---|
| Name | Bisdemethoxycurcumin NP Info | + | Alpha PD-L1 antibody Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Bladder cancer
[ICD-11: 2C94]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | IFNG | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MB49 | CVCL_7076 | Bladder transitional cell carcinoma | Mus musculus | ||
| In-vivo Model | To establish s.c. bladder cancer models, 1*106 MB49 cells in 100 uL PBS were injected in the right shaved flank of female C57BL/6 mice. | |||||
| Experimental
Result(s) |
Bisdemethoxycurcumin in combination with Alpha-PD-L1 antibody boosts immune response against bladder cancer. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Bisdemethoxycurcumin in combination with Alpha-PD-L1 antibody boosts immune response against bladder cancer. Onco Targets Ther. 2017 May 22;10:2675-2683. | |||
